CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 6513410
• 负责人: MARY ELLEN TAPLIN
• 金额: $ 10.66万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-09 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6513410
• 关键词: Hodgkin's disease; SCID mouse; androgen receptor; blood banks; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer prevention; cancer registry /resource; cancer rehabilitation /care; cancer risk; cell cycle; cell growth regulation; chemoprevention; clinical research; clinical trials; colony stimulating factor; colorectal neoplasms; combination cancer therapy; cooperative study; coping; cytogenetics; data management; esophagus neoplasm; female; gastrointestinal neoplasms; gene therapy; glioma; human subject; human therapy evaluation; leukemia; lymphedema; lymphoma; male; mammography; metastasis; minimal residual disease; mitoxantrone; molecular oncology; multidrug resistance; neoplasm /cancer; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer therapy; nonHodgkin's lymphoma; oncogenes; oncology nursing; prognosis; prostate neoplasms; quality of life; smoking cessation; statistics /biometry; tissue resource /registry

DESCRIPTION (adapted from the applicant's abstract): Since its inception in 1993, the University of Massachusetts Cancer Center has sought to elucidate new insights into normal and cancer cell biology. Investigators based at U Mass are beginning to translate this knowledge into clinical correlative studies and therapeutic approaches through the CALGB. For example, Dr. Mary-Ellen Taplin has described specific androgen receptor gene mutations that may target more effective treatments for hormone independent prostate cancer. These initial studies constitute one of the funded Correlative Science Studies through the CALGB and comprises one of the CALGB Core Labs. Based on our experience and substantial base in hematopoietic cell biology, a major focus of the U Mass Cancer Center has been in transplantion biology. Efforts have centered on (1) determining factors that enhance engraftment, (2) the development of entirely new transplant models using minimal myeloablation, (3) cord blood transplantation, (4) NOD-SCID preclinical transplant models to detect minimal residual disease, and (5) gene therapy approaches such as MDR1 transfer into normal hematopoietic stem cells. Many principles of hematopoietic stem cell biology "are now being applied to solid organ systems, with investigators at U Mass evaluating growth characteristics of both normal and neoplastic cells by defining the malignant stem cell" in solid tumor systems and defining autocrine and paracrine loop pathways of growth control. Stem cell "studies in breast cancer, prostate cancer, and glioblastoma" are ongoing and may provide important clinical correlative studies as companion studies to CALGB treatment protocols. Our Group Activities and Scientific contributions have increased significantly in the past four years. U Mass investigators in CALGB have contributed substantially to activities in Transplant, Breast Cancer, Prostate Cancer, Surgery, and Gastrointestinal Cancer. Administrative contributions through the Audit committee and other ad hoc committees have been substantial. Major efforts have led to improvement in accrual to Group Studies and improvement in the quality of data submitted on CALGB clinical trials.

描述（改编自申请人的摘要）：自成立以来， 1993年，马萨诸塞州大学癌症中心试图阐明 对正常和癌细胞生物学的新见解。 研究人员在美国 大众开始将这些知识转化为临床相关知识 研究和治疗方法通过CALGB。 博士举例 Mary-Ellen Taplin描述了特定的雄激素受体基因突变 这可能是针对激素非依赖性前列腺的更有效的治疗方法， 癌 这些初步研究构成了受资助的相关研究之一。 科学研究通过CALGB，包括CALGB核心实验室之一。 基于我们在造血细胞生物学方面的经验和坚实基础， 麻省大学癌症中心的一个主要焦点是移植生物学。 努力集中在（1）增强植入的决定因素， (2)开发全新的移植模型， 骨髓消融，（3）脐带血移植，（4）NOD-SCID临床前 移植模型检测微小残留病;（5）基因治疗 如MDR1转移到正常造血干细胞的方法。 许多 造血干细胞生物学原理"现在被应用于 实体器官系统，麻省大学的研究人员评估了生长情况， 正常和肿瘤细胞的特征，通过定义 实体瘤系统中的"恶性干细胞"和定义自分泌和 旁分泌环途径的生长控制。 乳腺干细胞研究 癌症，前列腺癌和胶质母细胞瘤"正在进行，并可能提供 作为CALGB伴随研究的重要临床相关研究 治疗方案。 我们的团队活动和科学贡献 在过去的四年里大幅增加。 调查人员在 CALGB为移植、乳腺癌和乳腺癌领域的活动做出了重大贡献。 癌症、前列腺癌、外科手术和胃肠道癌症。 通过审计委员会和其他特设委员会提供的行政捐助 各委员会都很充实。 作出了重大努力， 集团研究的应计费用和提交的数据质量的提高 CALGB临床试验。